贝瑞基因(000710) - 2020 Q1 - 季度财报

Financial Performance - Revenue for Q1 2020 was CNY 369,973,449.87, an increase of 11.14% compared to CNY 332,884,487.18 in the same period last year[7] - Net profit attributable to shareholders decreased by 62.79% to CNY 62,393,298.10 from CNY 167,685,430.87 year-on-year[7] - Basic and diluted earnings per share fell by 62.66% to CNY 0.1766 from CNY 0.4729 in the same period last year[7] - Net profit for Q1 2020 was CNY 60,048,341.05, a decrease from CNY 166,625,153.50 in the same period last year, reflecting a decline of about 64.0%[46] - The total equity attributable to shareholders of the parent company decreased to CNY 4,522,800,320.79 from CNY 4,692,226,477.59, a decline of approximately 3.6%[42] - The total comprehensive income for the period was -19,335,814.51 yuan, compared to -15,321,701.31 yuan in the previous period, indicating a decline of approximately 26.3%[51] - The net profit for the period was -19,335,814.51 yuan, which is a loss compared to -15,321,701.31 yuan in the previous period, reflecting an increase in losses of about 26.3%[50] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 152,146,155.23, a decline of 810.62% compared to negative CNY 16,708,011.17 in the previous year[7] - Cash and cash equivalents decreased by 24.66% to ¥310,009,184.51 from ¥411,490,040.83, primarily due to payments for raw material purchases and additional investments in a subsidiary[15] - The company reported cash inflows from operating activities totaling 280,599,799.64 yuan, down from 317,652,975.81 yuan in the previous period, a decrease of about 11.6%[53] - The company received $25,019,460.06 in cash related to operating activities, a notable increase from $15,419.73 in the previous period[57] - The ending balance of cash and cash equivalents was $4,288,037.44, compared to $7,558,088.52 in the previous period[58] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,040,861,492.18, a decrease of 0.91% from CNY 3,068,876,886.84 at the end of the previous year[7] - The total liabilities of the company increased from 721,830,243.65 yuan to 782,835,318.00 yuan, reflecting a rise of about 8.5%[38] - The company's non-current assets totaled 1,199,045,718.66 yuan, down from 1,216,282,931.60 yuan[37] - Cash and cash equivalents at the end of the period were 310,009,184.25 yuan, down from 341,925,439.80 yuan at the beginning of the period, a decrease of approximately 9.3%[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,455[11] - The largest shareholder, Gao Yang, holds 13.89% of the shares, amounting to 49,260,572 shares, with 36,450,000 shares pledged[11] - The major shareholder reduced its stake by 7,853,400 shares, representing approximately 2.21% of the total share capital[18] Research and Development - R&D expenses increased by 78.56% to ¥29,580,787.68 from ¥16,565,890.45, mainly due to increased investment in COVID-19 testing and third-generation sequencing reagent development[15] - Research and development expenses for Q1 2020 were CNY 29,580,787.68, significantly higher than CNY 16,565,890.45 in the previous period, indicating an increase of about 78.7%[45] Investment Activities - Investment income plummeted by 116.20% to -¥13,836,212.07 from ¥85,411,865.40, primarily due to the previous year's recognition of investment income from relinquishing control of a subsidiary[15] - The company reported a total of CNY 1,342,365.64 in other income for Q1 2020, with investment losses amounting to CNY 13,836,212.07[45] - Investment losses amounted to -13,862,799.99 yuan, compared to -9,735,687.19 yuan in the previous period, reflecting an increase in losses of approximately 42.5%[49] Corporate Actions - The company did not engage in any repurchase transactions during the reporting period[12] - The company has repurchased a total of 3,907,400 shares, accounting for approximately 1.1018% of the total share capital, with a total transaction amount of 160,386,379.29 yuan[22] - The company plans to implement an employee stock ownership plan using 3.9 million shares that have been repurchased, aligning with its long-term strategic development[23] - The company provided a guarantee for its wholly-owned subsidiary, Beijing Berry, for a credit line of up to ¥100 million to support its business operations[20] - The company acquired an additional 1.544% stake in Fujian HeRui Gene Technology Co., Ltd., increasing its total ownership to 20.956%[19] Management and Governance - The company did not undergo an audit for the first quarter report[60] - The company did not apply new revenue and leasing standards for the current reporting period[59]